Controlling blood glucose and blood pressure, inhibiting the activation of RASS, sodium-glucose co-transporter 2 (SGLT2), strengthening exercise, improving diet, and reducing body weight are the primary means of preventing and treating DN (6, 7), which are still difficult to meet the clinical needs, with a large number of DN patients developing ESRD irreversibly. This evidence concerns the gene SLC5A2 and liver dysplastic nodule.